Analysts think ADMA stock price could increase by 53%
Jun 08, 2025, 11:26 AM
-13.27%
What does ADMA do
ADMA Biologics, headquartered in Ramsey, New Jersey, specializes in manufacturing FDA-approved plasma-derived biologics for immune deficiencies and infectious diseases, employing 624 staff. The company went public on October 17, 2013.
6 analysts think ADMA stock price will increase by 53.46%. The current median analyst target is $31.62 compared to a current stock price of $20.61. The lowest analysts target is $21.17 and the highest analyst target is $36.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
